ENHANZE® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20-Reference-Cited by-同舟云学术

ENHANZE® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20

Published:2019-01-01 Issue:1 Volume:26 Page:98-106
ISSN:1071-7544
Container-title:Drug Delivery
language:en
Short-container-title:Drug Delivery

Author:

Locke Kenneth W.¹,Maneval Daniel C.¹,LaBarre Michael J.¹

Affiliation:

1. Halozyme Therapeutics, Inc., San Diego, CA, USA

Funder

Halozyme Therapeutics, Inc.

Publisher

Informa UK Limited

Subject

Pharmaceutical Science,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/10717544.2018.1551442

Reference73 articles.

1. Alexion Pharmaceuticals I. (2017). Alexion and Halozyme Enter License Agreement for ENHANZE Technology. Available at: http://files.shareholder.com/downloads/ALXN/6264479688x0x966094/4E5A51B2-4A6E-4C45-83C1-1F8B8373B8C0/ALXN_News_2017_12_7_General.pdf [last accessed 7 Sep 2018].

2. Alexion Pharmaceuticals I. (2018). Alexion development programs. Available at: http://alexion.com/research-development/development-programs [last accessed 19 Nov 2018].

3. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial

4. USE OF HYALURONIDASE WITH LOCAL ANESTHESIA IN OPHTHALMOLOGY

5. The impact of extracellular matrix on the chemoresistance of solid tumors – experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reversible protein complexes: Advancing subcutaneous delivery with controlled and sustained release of high concentration biologics;Journal of Drug Delivery Science and Technology;2024-10

2. Hyaluronidase overcomes the extracellular matrix barrier to enhance local drug delivery;European Journal of Pharmaceutics and Biopharmaceutics;2024-10

3. The safety of recombinant human hyaluronidase PH20 in nonclinical models: An overview of toxicology, pharmacology, and impact of anti-PH20 antibodies;Journal of Controlled Release;2024-10

4. Advances in tumor stroma-based targeted delivery;International Journal of Pharmaceutics;2024-10

5. Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+);Neurotherapeutics;2024-09